European Medicines Evaluation Agency Delays Verdict on Takeda Pharmaceutical Co. Ltd. Diabetes Drug to July

Japan's Takeda Pharmaceutical said on Friday it will fully cooperate with European regulators who are considering whether its diabetes drug Actos should remain on the market due to a possible link to bladder cancer.The European Medicines Agency (EMA), which had been due to give its decision this week, decided on Thursday to put back a decision until July, saying there were "still numerous issues that needed to be resolved" before it can make a recommendation on the drug's future use. Takeda said in a statement it would fully cooperate with the agency and submit all available data for its review. "We are confident of the therapeutic benefits and its importance as a type 2 diabetes treatment," Takeda said in the emailed statement.